IMV - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and thank you for standing by. Welcome to the IMV Inc.

First Quarter 2021 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Instructions]. [Operator like Officer. conference now Labbé, to hand Financial Chief to would over the Pierre I you. Thank go Please ahead.

Pierre Labbé

the am you Thank Executive period Business our Fred Officer name available update at conclude I CFO I follow will who am with the the is Hall, will operator. overview and will Officer; call. Pierre to you, Good summary question-and-answer results programs. the by Labbé, and about clinical at morning, first an quarter joined operational of IMV, Andrew conference Chief and begin of today our Chief our highlights clinical to company’s everyone. financial My pleased operational welcome call. for end and with Ors, will the the financial comments with I Fred the quarter. Andrew of and

are posted cause are performance our materially. press statements imv-inc.com. the forward-looking risks Web All applicable laws. statements that discuss Harbor and regarding with document pursuant today call, business financial based Safe securities filed could disclosure the future within this not forward-looking During expectations operating our MD&A They and guarantees the laws. all to The continuous securities events on release, made or are risks to our will statements future site current of uncertainties are actual results. Any performance. management and are differ comments of These to statement. provisions in applicable we are of of and forward-looking results meaning subject and These on discussed outlook at in make compliance the

to us. documents, to please wish receive of you a do not these hesitate contact If copy

I turn that from sell-side note call to will questions only over take we take Fred? Fred. Finally, now the will analysts.

Fred Ors

very you, cell our the Good welcome. important our to opportunity everyone, program. quarter, review Pierre. am first therapy today in cancer progress I T in morning, have pleased to including the and Thank milestone

footprint respect plan, to call, first maveropepimut-S new will clinical completed our regulatory the the and time, to DLBCL U.S. study, about a in expanding clinical Canada investigator-initiated are trials current combination X we beyond malignancies. progress provide this relapsed/refractory but in Our to expand that the cancer, countries. plan including the to later quarter the of about week, breast enrolling the study according year. study this filings have Phase With want At of other we which ongoing study. in hematological the of the continue I into this Andrew same this and announced started sites programs share in further to in in the we KEYTRUDA. [indiscernible] we initiation continue we study initiate Merck’s to and and Earlier we the have solid with details enthusiasm

to this opportunity study. our study, information shareholders. create line platform investigators response vivo identified cell all, the demonstration level to our of by the We in for patient of believe resistant survivin also treatment. of our tumor and First resection Oregon biomarker been Institute population. Cancer T to targeted test both and at providing early value treatment this has us It first discovery of to demonstrates study survivin can in unique the is the of Providence surgery, significant in This a our new time that adjuvant a after for therapy the opportunity a to an giving Portland, out come has has in access that thus complete and is potential

demonstrate which partly a a is funded by invasive of bladder immunotherapy an applications. X and collaboration the more we Both this member poor sponsored cell and further University have Quebec immunotherapy earlier exciting to This cancer We and surviving. of year is the will ability dual targeted prognosis. about also biology our and Center Laval the be been for through bladder first-in-human study platform our in targeted This this line Research are company track later in DPX-SurMAGE. the also is give in trial its the for cancer to half be family on second has MAGE with initiate of City. of the milestone study, will is and Phase generate of also presentation. AX targeting non-muscle the government therapies in protein detail for In various will study a trial IMV This by the associated potential with second this versatility treatment, T grants. to in the Andrew a

and cell the a throughout Goldfinch Chief CART serves and James, strategy cell Kuvalanka a Kyle XX brings also directed that company. therapy of medicine welcome guidance in approved FDA the the the wish precision of and in of Bio, them, of this leading and experience the Before well blueprint of track James Kyle therapy. founded Hall experience and immunotherapy, The as first to approval therapy Michael to as senior record Operating to at cell members, as and opportunity cell laboratory of a organizations, thank Chief the Mr. brings Wayne best and business played take dedication recognized Kalos, of in them and building the a Michael Penn, very Eli financings, two clinical immuno-oncology like Andrew, IMV global Kalos, University the Mr. led Pisano of biopharmaceutical the therapy Pennsylvania the a directing to the their recent of retirement turn Officer to to success Board he medicine, years program Kyle role over welcome and the including new forward. years for and Lilly. I conference and collaborations, Financial at this and and industry departure across currently wish I'd Kuvalanka development following both I going over annual leader years Janssen successful in as functions. such announced with Wayne Officer as forming Dr. Kymriah, ever meeting. to idea pioneer finance in XX the Dr. year's key want expert exceptional who including and T I negotiating following at internationally

Finally, a June management update. Today, Dr. reasons, XXXX. effective gave XX, Joanne Schindler resignation personal for her

firm we Over drive the remaining regulatory conference a a Officer her meantime, program. to wish Chief responsibilities and Joanne clinical best. now remarks. of Medical her hire for my Joanne maveropepimut-S track transition Chief the tenure, of Andrew In We over Medical as opening actively thank clinical continue And contribution to development with detailed a during more on Officer. who while keep the and our next her and working turn execute week, program. are our teams will will to her very recruitment in for registration. new towards will role And review concludes our I the This will

Andrew Hall

Fred. Good you, Thank morning, everyone.

bladder Before that the I I'm as emphasize, broad expanding clinical for X, get IMV has targeted cell the present progress second therapy I'd will excited into of time a utility on clinical steady dual to illustrated made in maveropepimut-S. specifics, DPX-SurMAGE, cancer. like to the first footprint asset, our first also investigated the T be Slide supporting the

has relapsed/refractory for have by would the tolerated, demonstration the to pending next easy maveropepimut-S of review we non-peptide the remind and with multiple and we're efficacy novel targets. clear occur months. platform. synergistic This cost outstanding value With Slide through DPX catalysts other said, technology other a will I ahead, effective like DLBCL DLBCL. administer, enabled unique X progress in is behind to importantly for over market and therapeutic in that with you success mechanism, exploring proposition I application is It to supports demonstrated manufacture. indications path that on starting to and potentially XX oncology compelling now well all of with set clinical its supported programs, also our Looking to maveropepimut-S many data now the IMV’s with that immunotherapies the other DPX-SurMAGE with

the with we in potential support parallel to Phase of mentioned, clinical involve Health Considering drug then two expand new and initiation year. towards anticipate to first to trial U.S. and this year. later our trial Europe and filed regulators This the to trial to will of may Canada initiated Xb the Fred ask sites, approval, quarter FDA Canadian and procedures prior this and we typical As investigational be application the the application end questions study. the the Australia

necessary strategy Our possible many trial is recruitment. quickly We rapid for is as ensure and here to activate competitive. to this know space to as the signs move as as

sites, timely initial of enrollment. that will clinical from are and conversations we prospective the drive KEYTRUDA differentiation Although maveropepimut-S confident with

so patient be year, two-year the and clinical clinical with evaluated a the evaluated in objective of systemic IMV’s DLBCL, to on trial plans compounds analysis patients is study during subjects cell briefly XX. least timeline, be XXXX have as or their last CAR-T -- PD-LX partial a and transplant criteria up as XXXX. have lines dosing All with I highlighted or the and and PD-LX a without XXX our randomized, As I now our third that will best apologize, parallel first treatment relapsed in exceptional an agent. or discuss year three-arm The three a combination of expression with look autologous complete achieving study response and we that of recurrent of data single group, for per to lead should predictive therapy. validate endpoint to received of arms presenting cancer therapy failed who this response biomarker SPiReL two-stage By ovarian Lugano in evaluate current stem prior reported reminder, assess the Across the maveropepimut-S study, to we measured two by forward this at evaluated the this interim success. Slide KEYTRUDA who primary refractory early of is subjects trial will response Simon baseline the rate the cyclophosphamide centrally for maveropepimut-S a number period. will will for arm anticipate shortly this a

and The the next to of tissue the understand expected population help here goal communicated, treatment are and is the this As inform previously DECIDE analyses stage biomarker to activity in are development. to completed from be quarter. predictive collected this ongoing better biomarkers the in potential trial

the treatment balance and natural the is with demonstrated tolerability With regimen a early patients fit. use in with ovarian efficacy in cancer, maveropepimut-S of

the this design the analysis Once second in trial a the meeting is with of the will year longer, really finalize is next trial. to half population we ability the request be the completed, larger this response will to As predict in important. of FDA the and

present scientific the in the also dataset will translational analysis an conference. upcoming of We

new except basket material update to study no the Before there's that trial. provide mention I'll the in to quickly respect investigator-initiated discussing breast cancer, with

of the radiotherapy cancer breast XX response this receptor potential be with and solid objective is remind evaluated the The the As conducted driving of breast be a of in and our that the week microenvironment footprint combination surgery. maveropepimut-S resectable, neoadjuvant study like this patients cancer. breast Phase summer. and study, the the be examine the in and The in validate population aromatase the of is at trial T lead Across Xb to all without to combination. later the cells announced negative maveropepimut-S demonstration begin hormone arms This patients immunotherapy, maveropepimut-S investigated cyclophosphamide subjects Oregon investigation will tumor Providence includes Institute remains therapeutic unmet positive/HERX-negative poor non-metastatic this expanded are a detail will nearly inhibitor with prior we of primary positive/HERX with XX% our treatment. neoadjuvant also evaluate tumors. that or in I of oncology is Portland endocrine with to the in to earlier receptor hormone understood of Cancer three-arm specific you to in survivin high, need The study investigator-initiated will well expected with efficacy in an the would to will safety in cancer. maveropepimut-S hypothesis three considering

and tumor microenvironment. translation study of analysis to include and the extensive this such, tissue of serum will activity markers in an identify within collected the tumor As also

particularly about We’re in cancer. therapeutic of breast enthusiastic the maveropepimut-S potential

high understanding know different that of we may positively maveropepimut-S is our mentioned, but other a solid it future platform clinical markers deepen with survivin that identify in both new Fred will only DPX in of this this tumor in As and type. the expression. derisk also correlated patients, with negative expression studies population and Not outcomes will tumors trial survivin

is cancer a kidney. to survivin briefly really Slide which in antigens, I'd will cell excited and protein and targeted MAGE-AX and survivin including our formulated on introduce protein T preclinical platform from frequently dual human important with team therapy of completed selected XX, lung therapy. product family DPX bladder, DPX platform and and clinic. be member peptides MAGE-AX. therapy Selected targeted cancers, peptides product, second Dr. new the combines Fradet form clinical Moving MAGE-AX have are a like T types activating to This MAGE DPX-SurMAGE, the and to of successfully DPX-SurMAGE. of two we this dual the expressed evaluations move a his into to the and cell is

Quebec University researcher Dr. cancer Fradet by and Our first immunotherapy combination team. his in investigation with be with in Research cancer. sponsored DPX-SurMAGE of at cancer in Hospital This Laval a Yves bladder and non-muscle be patients will led is muscle the bladder monotherapy in invasive trial as in surgery inhibitor IMV a will Dr. Fradet of at City. checkpoint and professor invasive Center

will of recurrent be and transurethral is half prior grade high the initiated DPX-SurMAGE bladder The in non-muscle first without and resection or this invasive study to year. scheduled with second low grade evaluate cyclophosphamide cancer, to of

second evaluate DPX-SurMAGE of the which cystectomy. prior bladder following to an The sequentially, treatment invasive cancer will will anti-PD-X and muscle study, initiated be and for

the this to there of provide program review Pierre quarter. you. the respect pass to quarter’s will in COVID-XX I I'll quickly no the update financial, Pierre, to conference a material for back back mention the that with Before conference turning to is

Pierre Labbé

Thanks, Andrew.

change which was economic we Canadian dollar was primary presentation change adopted currency Prior the into to The dollar our presentation U.S. our accounting Effective from as a prospectively. operate. the dollar. the to date, in currency. to want get was January environment applied XXXX, change X, more currently functional Canadian I functional dollar the in reflect currency and the and I we Before the this functional functional policy. U.S. in underline to The made the in currency closely financial, the

together currency, For information three-month XX, are the presented change in the as for comparative presentation dollars in financial XXXX. March applied XX, statements December retrospectively, ended and of U.S. and was it therefore the the with period XXXX

more X ended three-month for find the information the March XX, can XXXX. You page on Note financial period and of statements this

Now the financials. back to

increase to ongoing were for expenses XXXX, mainly decrease expenses trial X.X and million decrease offset period million DPX-SurMAGE. DPX-COVID-XX. million pre-clinical related the manufacturing $X.XX to the quarter March by from last For XXXX ended and year. of per compared XX, per in compared X.X to period grants the personnel the three-month timing same $XXX,XXX headcount increase same three-month QX the in government increase an DPX-Survivac or due was The ended also million activities for is $XXX,XXX million DPX-COVID-XX. Canadian increased an for mainly expenses government of loss explained R&D expenses in an $X.XX year. to XX, increase G&N It million comprehensive totaled X XXXX. of of to year, This government the was development and loss by and for due share to entirely last $XXX,XXX in compared a share costs The X.X The or X.X the by March X.X the from basket for to premium. X.X partly for related is insurance the explained period development of million to and this assistance The was net in the last

the XX.X of cash had of million company XXXX, equivalents XX, March of end million XXXX. compared XX.X to As cash the and at

quarter We and operational cash, These the is For change is identified anticipated based the going to which sources first that although activities $X.X funding assumptions difficult plans we will place capital cash first any XXXX. existing use It any of plan, and non-dilutive equivalents other potential runway. account not on decreased that X.X of may cash X.X activities which it take and the and of million. potential the by and/or fund million assessing our investing for until are based corporation’s and on of At-The-Market the expenditure equivalents estimates $X and exchange the magnitude corporation and on a operations of and also Financing come million of have purpose the CapEx cash concern, cash impact cash expenses, and effect million predict generated from could as million. XXXX. does timing The activities. operating in generated requirements operating $X.X by proceeds requirements, cash the gross current financing facility Cash into generated foreign used it of in ATM of million quarter funding. of in activities or cash in $X.X

million the of of were XX.X common total As a was and of XX, options, number issued outstanding. X.X stock and and warrants XXXX, outstanding shares May million DSUs

note take Thanks the three-month attention. company’s MD&A turn that his available XXXX I on period for for EDGAR ended on call comments before related site. financial the and the Web over Finally, your Q&A Fred? statements the will the SEDAR, session. for to and the Fred XX, corporation's closing on March are And back now

Fred Ors

Thanks, Pierre.

a we Our new should pharma have the targeted members same guidance broadening presentation of and stage of made the able quality pipeline indication we're company will and new you good give path indications on provide tomorrow. footprint clinical new our to recent our towards in T valuable maveropepimut-S therapies. At cell on today time, to advancing the the today from attract a expanding Board to significant level progress next high IMV a that successful

support Thank dedicated also deliver partners, attention. for your As progress are improved are Operator, shareholders. grateful the stakeholders, making we quest for to we and continue now outcomes continued for our of take patients, you employees, in to we our questions. ready all

Operator

[Operator Instructions].

go Please BTIG. of ahead. Shrader Tom of line the from comes question first Your

Your line is open.

Kaveri Pohlman

have There like breast talk about aren't your in patients rationale and therapies setting Thanks immunotherapies of for questions. seem respond Kaveri our approved inhibitors Hi. -- HR for a positive/HERX I This one. BTK for to and cancer? to you lot selecting negative just taking Can is this well Tom.

Fred Ors

Thanks answering here. Andrew it is and maybe for your I'll start complete. Fred question. This can

found the really rate identified currently for be being low. that It's one XX%. So that what explaining, which treatment. survivin women biomarker are that it’s setting, neoadjuvant our drugs at was neoadjuvant so first, in looking is T treated it's non-responders, upregulated response have, resistant look are survivin below stage, the really cell used found in of Andrew But because potential investigators majority setting of of like the they they therapy the the the at reasons most being of out those you that could was you the is the for neoadjuvant when and the at that, quite to

So find two them. cell But and many are it, about times, saying important are much for they Really things very found you've us T work. therapy making us. believe we we that heard that what didn't there like this we

The pharmacokinetic with one blood bar to cancer you that of in a in want add T of is Not And best again of setting of we first the of patients, us. a biology with perfect or the platform, neoadjuvant the neoadjuvant the also these, on really same commercial thing second low place more to time, And a in [ph] immunotherapy so which line creating but setting. probably only the of is plays in it's the it's at all I Andrew, meaningful the for this. cancer associated for role evolution cancer, don't the DPX. And really cells setting, know, where are quite is the this here if be. in targeting is that case have in we controlling the dose something doing our to is something treatment. resistance

Andrew Hall

can population the it's expression be IMV population population. with Yes, think mentioned Fred more a more a be potentially population the we high following is a maybe and to following competitive. largest earlier recognize little in to obviously breast we understand and solids that to a we’re breast technology. cancer it's is with this to appears more lines this as [ph] we the that the treatment population step immune-abled this survivin now I’ll to important exciting other cancer other driver as biology very follow line the really Commercially, into of of population of that maveropepimut-S. But and is just in what very -- of treatment expansion will IMV footprint with a beyond an where largest tissue compelling a of biology able And is idea I really in rationale now of the as that in targets, improved to behind find size to we're showing for a And add reason reasons even this are available creating that identify in strategic idea go we're do for that in then collect forward further therapeutics importantly, that resistant appealing for sort point therapeutic for flavor. the to late the other respect analysis it glad

an it's is So reiterate. think excellent to the observation that question important and biology the following we're I

Kaveri Pohlman

congrats and you the Thank Great. on progress.

Fred Ors

you. Thank

Operator

next from ahead. go Wainwright. Your of Please Joe question Pantginis H.C. comes

open. is Your line

Joe Pantginis

Good taking guys. in Good and to go. next sad your Hi, see steps. And the thanks morning question. luck for Joanne

vein about in just So the on to benchmarking. talking breast here, just continue wanted continuing cancer

upcoming let you fair to about me conducting fair be? are responses rates a know about what you could with the but going And would the to diseases talked patients see under study, analyses certainly at is essentially And Thank since XX%. translational response the be first, the what regard a So inclusion improvement for any this you. you'll above a you of meaningful on Is I point? be that that then role stages statement if that responses it broadly then the based know that implicate of consider immunotherapy? being you to talked this criteria,

Fred Ors

the reduction, it before surgery. you and Like early provide see but are very women of down-staging of aromatase regimen the on can neoadjuvant some chemotherapy on don't lot setting analysis it's some you, tumor typically line specific and said, Thank basically benefits sometime where tumor, or of with we depending a the Joe. inhibitors of certainly state treated the

than So where like has limited benefits used we’re is other this that's surgery. really for adjusting and

immune And of to or of question, the improve that's The is you so like create early to your answer to like know, performance an outcomes activation in we would And response as long-term why patients be what difference really And on really a we be thanks therapy yes, with make can T is immunotherapy the at the like. for this of the where that's activity will because question tumors. patients. asking immunotherapy, who to too yes. immune the we able see potential the to cell line, that

be between make able bigger the surgery, to of will T if treatment can We see therapy see impact for currently and the difference is and start what cell a used really neoadjuvant. than

Joe Pantginis

I'll could supply and about have Thank helpful. just chains the manufacturing if just United concerned for watching too much. different the you or admit, just you. everyone's the maybe And second. across States talking That’s a in news shift and so world. gears And just I'm about I what

against types cost that's your and especially encouraging, about immunotherapies have case obviously assets, other for manufacturing the low very you you therapies. very of compare So when made cellular or

supply with be that ever that chain even any sourcing to manufacturing potential might shouldn't with if you be the about it's steps what peptides So regard consider limiting that the if anything could sort or issues? concerned there's rate about, of external like process any concerned or anyone said, concern cause might

Fred Ors

the quite the of But and manufactured mRNA the vaccine. the developing, the the and composition technology. both nanoparticle technology are have delivery that the which say is it are we LNP in source lipid issues from we are a what not to Well, first -- manufacturing for different world, we reason drug technology technologies all, chain experiencing issues it's of is supply that chain is way any I luckily, related is supply to are

about you developing composition, this we at are world very only it own portfolio different a we using lipid one to if All really the think are different. on a the knowledge, -- platform. this. the was invented this we're and as time And like the that strong my in platform by company you elements it’s IP the So know, with

So it issues. protects those supply from us chain

On to peptides I of any issues the don't factor so things, lot of the peptide more that than suffer to manufacturing. would manufacturing. generation lot in the There's trends foresee vaccines, vaccines by There's chain don't approved are FDA, so limiting there's supply development, we going a in a future of next the capacity peptide XXX again, for not the be vaccine side peptide world in a say. peptide related we of

Joe Pantginis

Got it. that Thanks appreciate color. a Fred, I really lot.

Fred Ors

Thanks.

Operator

Instructions]. [Operator

Your comes next Tenthoff ahead. question Ted Sandler. Please from Piper of go

Your line open. is

Ted Tenthoff

that sort to indications? studies? do in really into that Will there? between adding maybe cyclophosphamide Great. all all have is, the be the ends wanted maveropepimut differences the And know Thanks. of DLBCL. a driven? future in updates single you and how the of Xb arm thanks you ask there removed fitting Thanks, the And guys. KEYTRUDA progress. data you understanding the of what and And not contribution to anything, all the DLBCL I would other for dose study about kind is on from are it think again, I that And maveropepimut. of get If that in better up other low study, showing of cyclophosphamide cyclophosphamide be that see the

Fred Ors

Ted. Thanks,

answer testing first the are a dose is of drug first contribution of good. the part treatment. to we is the If profile -- The contribution, yes, keep available. going answer we So design that's CPA we're CPA safety It's the see study. of in in low the

maveropepimut-S KEYTRUDA and it science benefit, immunotherapeutic it keep is the we'll So remove it There a be around of we'll lot other won't problem. of just with and preclinical a meaningful then agents. cyclophosphamide as combination. simply any show doesn't use If the

the to in are DLBCL. T technology we with cell this first generate However, activity therapy

should there's to confirmation that believe that's this So the be thing decision, combination. be I for in looking indications? But Will It's into the in for is the way, same cancer, really the and what ovarian we're to human going it at. for we the that's Either certainly time, doing. to access could at case dose be the not are what the other differences of important really be base be the there market something translate can advance and are let's chemotherapy for same between, tumor, said, cells in But, tumor you DLBCL. in the T and might ovarian. microenvironment, DLBCL the it in help and example, example, [indiscernible] like where case say, going

to the data forward want as move really we for we base clinical CPA. decision on So

Ted Tenthoff

Okay, year. really I'm to it. cool. data excited this Awesome. more see I coming appreciate

Fred Ors

Thank you, Ted.

Operator

Your comes from Please go next Capital of Chelsea Stellick Markets. iA question ahead.

is line Your open.

Chelsea Stellick

have I the two side. or just finance questions one quick just on

sort XXXX. if guess what the of use although again. is future enough more fund quarter I just accessing gauge want funding the to and of I I or the first be? of ATM million guess operations. the just specificity kind further clarity funds So on XX till would to I'm to appetizing get of the future through for trying And so, funding operations

Fred Ors

Pierre, want take do to that you one?

Pierre Labbé

Chelsea. Thanks, sure. Yes,

we the of plan specific the if price use any it have in it. share It's is the For used to that. company access for and of how the think ATM, past. I a terms sense that And makes we things have use can we tool like there don't believe that that to that's we in

the guarantee use XX next no we months. that there's in ATM So the will

few of duration that the in mean it use mention that of in use we the but take any won’t just next So have we to into cash, cash doesn't months. in ATM, account wanted the don't the we that and the it

Chelsea Stellick

fair. that’s Okay,

Fred Ors

are to with doing what you do the platform? BD Andrew? add we the that Andrew, on want Maybe, to activities

Andrew Hall

To well. discussions. was that Sorry, have healthy on very we for the non-dilutive making appetite are progress in a And our I those mechanisms we're in as clear, funding I'm by encouraged mute. make

of our leaning in into technology is term long development in think delivery I we an therapeutic midterm do and create maybe opportunities pipeline anything an to fundraising sort a for do of stream more important the are company that by complementary a we either it's mechanism. targets, element opportunities sort other mechanism not the drug peptide is we creating open business by development open funding mechanisms. we remain And through possibility that ultimate momentum. perhaps start business other of will for ATM size, an our And or need the for non-dilutive that as to to mechanisms value of to revenue the as to balance to create through a our opportunities IMV through

Chelsea Stellick

from Thank guess more just me. I Perfect. question you. one

headcount, can year? With expect over G&A the sort next for the growing we what of

Fred Ors

Yes.

of an we costs to we to related we June insurance had G&A, the of G&A saw as in terms related increase directly expect in first the the the an because, I headcount increase premium quarter was For the XXXX. mentioned, that and in don't increase that in

to related G&A. people addition of nothing So more in the

Chelsea Stellick

half second forward you. me. there's year a for events. analyst That’s of I'm the of all sort Thank quite the And few when looking to

Operator

time. There the I further will turn remarks. questions to are no this Ors at call Frederic closing for over

Fred Ors

all good very you this and and questions, a rest much have time Thank the day. morning your the for of good everyone

Operator

call. gentlemen, you today's this Thank and conference concludes for Ladies participating.

now disconnect. You may

IMV (IMVIF) 12 May 212021 Q1 Earnings call transcript